Investors

Quantum Genomics is listed on the Euronext Growth stock exchange market in Paris since April 10, 2014 and is trading in the U.S on the OTCQX market since July 11, 2017.

Press releases

Find all our press releases by year, by clicking on the button below.

PRESS RELEASES

Financial documents

Find all the financial documents relating to our investors classified in three main categories, by clicking below.

Investors presentations

Find all the investor presentations listed by year, by clicking below.

SFAF Presentation – April 9, 2019 PDF
AHA Presentation – Chicago – November 10, 2018 PDF
Webcast – November 12, 2018 WEBCAST
Webcast – April 20, 2018 WEBCAST
Biotech and Money Conference – London – November 14, 2017 WEBCAST
Large & Midcap Event – October 4-5, 2017 PDF
Rodman & Renshaw Conference – September 12, 2017 PDF WEBCAST
KOL Day presentation – June 19, 2017 PDF
Conference call/webcast presentation – June 19, 2017 PDF WEBCAST
Biotech Agora Conference – November 8, 2016 PDF
Top-line results – QGC001 Hypertension Phase IIa – Conference Call September 29, 2016 PDF
Rodman & Renshaw Conference – September 13, 2016 PDF
Investors presentation – June, 2016 PDF
Investors presentation – European Smallcap Event 27 & 28 april – 2015/04 PDF
Investors presentation – Public equity offering on Alternext Paris – 2015/01 PDF
Investors presentation – Large & Midcap Event – 2014/10 PDF

Equity research

FirmAnalyst
Genesta Finance/AurgalysJean-Pierre Loza – jp.loza@aurgalys.com
EdisonMaxim Jacobs – mjacobs@edisongroup.com
Invest SecuritiesOlga Smolentseva – osmolentseva@invest-securities.com
Kepler Cheuvreux Equity ResearchThomas Landemaine, Ph.D. – tlandemaine@keplercheuvreux.com
Gilbert DupontJamila El Bougrini

Quantum Genomics is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Quantum Genomics’s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Quantum Genomics or its management. Quantum Genomics does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Analyst report Jean-Pierre LOZA - 2019/11/28 PDF
Analyst report KEPLER CHEUVREUX EQUITY RESEARCH - 2019/10/25
To access the analysis, click on the link Research public access and fill in its status to create an account LINK
Analyst report INVEST SECURITIES 2019/10/10 PDF
Analyst report GILBERT DUPONT – 2019/10/10 PDF
Analyst report EDISON - 2019/10/08 PDF
Analyst report Genesta Equity Research (ex-Aurgalys) – 2019/06/18 PDF
Analyst report Invest Securities – 2019/06/11 (french only PDF
Analyst report Invest Securities – 2019/05/17 PDF
Analyst report Invest Securities – 2019/04/02 PDF
Analyst report Edison – 2019/04/01 PDF
Analyst report Gilbert Dupont – 2019/02/25 PDF
Analyst report Genesta Equity Research (ex-Aurgalys) – 2018/11/22 – Excellent Top line results from Phase IIb NEWHOPE in hypertension PDF
Analyst report Gilbert Dupont – 2018/11/21 – Who will resist Firibastat? PDF
Analyst report Invest Securities – 2018/11/14 – NEW-HOPE for success in hypertension PDF
Analyst report Genesta Equity Research (ex-Aurgalys) – 2018/11/05 – Quantum Genomics accelerates its R&D in anticipation of several clinical study results PDF
Analyst report Edison – 2018/10/09 – NEW-HOPE data to be presented at AHA PDF
Analyst report Edison – 2018/09/10 – NEW-HOPE enrolled much faster than expected PDF
Analyst report Edison – 2018/07/13 – A little company going after big indications PDF
Analyst report Edison – 2018/06/28 – The QUORUM trial PDF
Analyst report Aurgalys – 2018/04/24 – “BAPAIs Fast Growth”, Quantum Genomics strategy for the next three years PDF
Analyst report Edison – 2018/04/23 – Accelerating timelines PDF
Morning Invest Securities – 2018/04/23 – Accelerating clinical developments (french only) PDF
Analyst report Aurgalys – 2018/04/09 – 2017, an intensification of clinical activity with NEW-HOPE and QUID HF PDF
Analyst report Edison – 2018/04/04 – NEW-HOPE trial recruiting rapidly PDF
Analyst report Aurgalys – 2018/02/16 – Aurgalys is contracted by Quantum Genomics to provide equity research PDF
Analyst report Aurgalys – 2017/10/25 – Quantum Genomics published its H-1 2017 financial results and launched the NEW-HOPE study in the United States PDF
Analyst report Edison – 2017/10/05 – NEW-HOPE trial launched PDF
Analyst report Invest Securities – 2017/07/27 – Strong upside at the price of a high dilution (french only) PDF
Analyst report Edison – 2017/06/27 – QGC001 clinical results PDF
Analyst report Aurgalys – 2017/06/20 – A decisive phase II in the US to validate QGC001’s efficacy PDF
Morning Invest Securities – 2017/06/19 – Signs of Efficacy on Patients With High HBP (french only) PDF
Analyst report Edison – 2017/04/04 – Accelerating clinical studies PDF
Invest Securities flash – 2017/04/03 – 2016 annual results (french only) PDF
Analyst report Aurgalys – 2017/02/17 – Quantum Genomics strengthens IP on BAPAIs while preparing the US phase 2 trial in hypertension PDF
Invest Securities Biotech Review – 2017/01/26 – Quantum Genomics, top pick H1 2017 PDF
Initiation of coverage Edison – 2016/11/28 – Quantum Genomics : The next generation of cardiac drugs PDF
Invest Securities flash – 2016/10/11 – A first step well underway (french only) PDF
Analyst report Aurgalys – 2016/10/05 – Quantum Genomics establishes first clinical proof of efficacy of QGC001 in hypertension PDF
Invest Securities flash – 2016/07/04 – QGC001 attendu en septembre (french only) PDF
Analyst report Aurgalys – 2016/05/24 – Extended US patent protection for Quantum Genomics’ drug candidates PDF
Analyst report Aurgalys – 2016/04/04 – Quantum Genomics raises €8.6M to fund Phase II clinical programs in hypertension and heart failure PDF
Invest Securities flash – 2016/03/29 – Sécuriser pour mieux avancer (french only) PDF
Analyst report Aurgalys – 2016/01/06 – 2016, a decisive year for Quantum Genomics PDF
Analyst report Aurgalys – 2015/10/12 – Quantum Genomics gets first positive DSMB with QGC001 in hypertension PDF
Aurgalys analyst report – 2015/07/08 – Quantum Genomics accelerates clinical development of QGC101 in Congestive Heart Failure PDF
Invest Securities flash – 2015/06/30 – Positive results in the dog (french only) PDF
Invest Securities equity research – 2015/05/28 – Initiation of coverage: “APA”for the bigpharmas? PDF
Aurgalys equity research – 2015/02/25 – €12.9M in Equity Financing: Quantum Genomics makes investor’s hearts beat PDF
Invest Securities equity research – 2015/01/27 PDF
Aurgalys equity research – 2014/11/04 – Quantum Genomics could revolutionize the hypertension market PDF

Shareholder letter

Welcome to the page dedicated to our shareholder Letters. We hope to make this communication tool a way of providing you with in-depth information on a regular basis to help you understand our strategy and how our projects are progressing.

Shareholder letter – April 2019 READ
Shareholder letter – November 2017 READ
Fact Sheet – October 2017 READ
Shareholder letter – November 2016 READ
Shareholder letter – June 2016 READ

General meetings

The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 27, 2019, at 10 am, in the offices of AARPI, located 36 Avenue Hoche, 75008 Paris.

The notice of meeting was published in the May 22, 2019 issue of the BALO (french only) PDF
Text of the resolutions (french only) PDF
The postal voting form (french only) PDF
Power model (french only) PDF
Delegations summary (french only) PDF
Voting results (french only) PDF

The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 14, 2018, at 10 am, in the offices of AARPI, located 36 Avenue Hoche, 75008 Paris.

The notice of meeting was published in the May 9, 2018 issue of the BALO (french only) PDF
Text of the resolutions (french only) PDF
Candidates to the Board of Directors (french only) PDF PDF
The postal voting form (french only) PDF
Power model (french only) PDF
Voting results (french only) PDF

The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 8, 2017, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.

The notice of meeting was published in the May 3, 2017 issue of the BALO (french only) PDF
Text of the resolutions (french only) PDF
The postal voting form (french only) PDF
Power model (french only) PDF
Minutes PDF

All the resolutions were approved during the general meeting.

Holders of redeemable share subscription warrants issued on June 8, 2017 (BSAR 2017) are called to attend the Annual General Meeting on June 15, 2016 at 9:50 am in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.

The notice of meeting was published in the May 3, 2017 issue of the BALO (french only) PDF
Text of the resolutions (french only) PDF
The postal voting form (french only) PDF
Power model (french only) PDF

The next annual general meeting of shareholders of Quantum Genomics company will be held Wednesday, June 15, 2016, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.

The notice of meeting was published in the May 9, 2016 issue of the BALO (french only) PDF
Text of the resolutions (french only) PDF
The postal voting form (french only) PDF
Power model (french only) PDF
Minutes PDF

Holders of redeemable share subscription warrants issued on March 14, 2016 (BSAR 2016) are called to attend the Annual General Meeting on June 15, 2016 at 9:50 am in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.

The notice of meeting was published in the May 9, 2016 issue of the BALO (french only) PDF
Text of the resolutions (french only) PDF
The postal voting form (french only) PDF
Power model (french only) PDF

The general meeting of shareholders of Quantum Genomics company will be held Tuesday, December 22, 2015, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.

The notice of meeting was published in the November 16, 2015 issue of the BALO (french only) PDF

The general meeting of shareholders of Quantum Genomics company will be held Tuesday, June 30, 2015, at 10 am, in the offices of Orsay Avocats Associés, located 146/150 Champs Elysees – 75008 Paris.

The notice of meeting was published in the May 25, 2015 issue of the BALO (french only) PDF

The general meeting of shareholders of Quantum Genomics company will be held Monday, June 30, 2014, at 4 pm, in the offices of SCP Lerner Friggeri & Associés (Cabinet Orsay), located 146/150 Champs Elysees – 75008 Paris.

The notice of meeting was published in the May 26, 2014 issue of the BALO (french only) PDF
Minutes (french only) PDF

Shareholding

Share capital of Quantum Genomics
Date: October 31, 2019

0

Total number of shares

0

Total number of voting rights

Including 325,000 new shares issued during October, 2019, in accordance with the contract of Equity Line financing concluded with Kepler Cheuvreux on March 5, 2018.

Main stock information

ISIN CodeFR0011648971
MnemonicALQGC
Listing marketAlternext – Euronext Paris
PEA (Share savings plans) and PEA-PMEYes
SRD (Deferred settlement)No

Capital breakdown as of January 31st, 2019

Governance

Quantum Genomics is a limited company with a board of directors. The compositions of the Board and Executive Committee of the Company are set out in the Company tab.

Financial calendar

All publications will happen after the close of the Euronext markets.

March, 28th 2019

2018 Annual Results

June, 27th 2019

General Meeting of Shareholders

October, 3th 2019

2019 Half-Year Results

Contacts - Investor Relations

For questions of financial order, please contact Marc Karako by completing the form.